R
49.26
0.38 (0.78%)
| 前收盘价格 | 48.88 |
| 收盘价格 | 48.97 |
| 成交量 | 26,238 |
| 平均成交量 (3个月) | 270,879 |
| 市值 | 920,170,048 |
| 市盈率 (P/E TTM) | 2.92 |
| 预期市盈率 (P/E Forward) | 9.29 |
| 价格/销量 (P/S) | 3.45 |
| 股市价格/股市净资产 (P/B) | 2.14 |
| 52周波幅 | |
| 利润日期 | 3 Nov 2026 |
| 营业毛利率 | 18.31% |
| 营业利益率 (TTM) | 23.95% |
| 稀释每股收益 (EPS TTM) | 2.09 |
| 季度收入增长率 (YOY) | 80.60% |
| 季度盈利增长率 (YOY) | 1,845.90% |
| 总债务/股东权益 (D/E MRQ) | 544.23% |
| 流动比率 (MRQ) | 2.20 |
| 营业现金流 (OCF TTM) | 35.59 M |
| 杠杆自由现金流 (LFCF TTM) | 3.40 M |
| 资产报酬率 (ROA TTM) | 18.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Rigel Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
2.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 相对估值 | 5.0 |
| 财务健康 | 5.0 |
| AI Insight | NA |
| 平均 | 2.00 |
|
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.66% |
| 机构持股比例 | 79.25% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合